A Randomized Invasive Cardiac Electrophysiology Study of the Combined Ion Channel Blocker AZD1305 in Patients After Catheter Ablation of Atrial Flutter
Authors:
- Pekka RaatikainenPRPekka Raatikainen
- Håkan WalfridssonHWHåkan Walfridsson
- Anders EnglundAEAnders Englund
- Finn HegbomFHFinn Hegbom
- Ole-Gunnar AnfinsenOAOle-Gunnar Anfinsen
- Knut GjesdalKGKnut Gjesdal
- Steen PehrsonSPSteen Pehrson
- Susanne JohanssonSJSusanne Johansson
- Lars FrisonLFLars Frison
- Anders R BerggrenABAnders R Berggren
- Nils EdvardssonNENils Edvardsson
- 1 September 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 56 (3) , 300-308
Abstract
This study assessed the cardiac electrophysiological and hemodynamic effects of an intravenous infusion of the combined ion channel blocker AZD1305. After successful ablation of atrial flutter, patients were randomized to receive placebo (n = 12) or AZD1305 (n = 38) in 4 ascending dose groups. Electrophysiological and hemodynamic measurements were performed before and commencing 20 minutes after start of infusion. Left atrial effective refractory period increased dose and the primary outcome measure increased dose and plasma concentration dependently, with a mean increase of 55 milliseconds in dose group 3. There was a corresponding increase in right atrial effective refractory period of 84 milliseconds. The right ventricular effective refractory period and the paced QT interval also increased dose and concentration dependently, by 59 and 70 milliseconds, respectively, in dose group 3. There were indications of moderate increases of atrial, atrioventricular nodal, and ventricular conduction times. No consistent changes in intracardiac pressures were observed, but there was a small transient decrease in systolic blood pressure. Adverse events were consistent with the study population and procedure, and there were no signs of proarrhythmia despite marked delay in ventricular repolarization in some individuals. AZD1305 shows electrophysiological characteristics indicative of potential antiarrhythmic efficacy in atrial fibrillation.Keywords
This publication has 15 references indexed in Scilit:
- New developments in atrial antiarrhythmic drug therapyNature Reviews Cardiology, 2010
- Assessment of the Ion Channel-blocking Profile of the Novel Combined Ion Channel Blocker AZD1305 and Its Proarrhythmic Potential Versus Dofetilide in the Methoxamine-sensitized Rabbit In VivoJournal of Cardiovascular Pharmacology, 2009
- Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009The Journal of Clinical Pharmacology, 2009
- Literature‐based evaluation of four ‘hard endpoint’ models for assessing drug‐induced torsades de pointes liabilityBritish Journal of Pharmacology, 2008
- Cellular basis of drug‐induced torsades de pointesBritish Journal of Pharmacology, 2008
- Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approachesEP Europace, 2008
- Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009Heart Rhythm, 2006
- Issue HighlightsCirculation, 2006
- Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem?Journal of Electrocardiology, 2004
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998